Cardiovascular and metabolic trajectories in men engaged in a multidimensional preventive care program: a prospective observational study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objectives
To describe within-individual changes in cardiometabolic, functional and neuroendocrine markers between two standardized evaluations in men engaged in a structured preventive care program, and to examine transitions across clinical risk categories.
Design
Prospective observational cohort study using routinely collected data; paired within-individual analyses.
Setting
Single preventive health center in Paris, France, offering a standardized multidisciplinary assessment with individualized lifestyle, supplementation and, when indicated, pharmacological recommendations.
Participants
279 men aged 18 years or older with a first evaluation (CU1) between October 2022 and November 2025 and a second evaluation (CU2) by May 2026 (32.3% of 865 eligible men); median interval 13.3 months (IQR 12.0–15.6). No exclusion criteria were applied.
Primary and secondary outcome measures
Within-individual change in continuous markers (Hodges– Lehmann estimate, 95% CI; Benjamini–Hochberg adjustment over 36 tests) and transitions across fixed clinical thresholds (paired odds ratios).
Results
Median age was 51.2 years, BMI 24.5 kg/m² and SCORE2 2.9%. Visceral adipose tissue mass decreased (Δ −49 g, 95% CI −80.5 to −18.5; q=0.006), with small decreases in body mass and fat mass. Handgrip strength increased (right +2.35 kg, 1.70 to 3.00; left +1.70 kg, 1.05 to 2.30; q<0.001). HDL cholesterol increased (+3.5 mg/dL, 2.5 to 4.5; q<0.001), with decreases in the triglyceride/HDL and total/HDL ratios. Blood pressure, LDL cholesterol, fasting glucose (after adjustment), insulin, HOMA-IR, SCORE2 and salivary cortisol and DHEA did not change. The proportion of men below the grip strength reference value decreased from 60.1% to 47.6% (paired OR 0.34, 0.19 to 0.61) and with HDL cholesterol ≤46 mg/dL from 26.7% to 16.5% (OR 0.25, 0.12 to 0.54).
Conclusions
IIn this selected, health-engaged population of men who completed both evaluations, changes in a favorable direction were observed for handgrip strength, HDL cholesterol and visceral adiposity, whereas blood pressure, LDL cholesterol, glycemic markers and SCORE2 were stable. Without a comparison group, these changes cannot be distinguished from regression to the mean, test–retest effects or secular trends.
Strengths and limitations of this study
-
Standardized assessment protocol applied identically at both evaluations, combining clinical, laboratory, DEXA body composition, functional and salivary neuroendocrine measurements in the same individuals.
-
Paired within-individual analyses of 36 markers in 279 men, reported as effect estimates with confidence intervals and a global false discovery rate adjustment, with sensitivity analyses by follow-up interval and calendar period and a comparison of returners with 586 eligible non-returners.
-
Single-arm design without a comparison group: the observed changes cannot be distinguished from regression to the mean, test–retest effects, participation effects or secular trends.
-
Highly selected population of urban, socioeconomically advantaged, health-engaged men, of whom 32% returned for a second evaluation, limiting generalizability to the general population and to high-risk groups.
-
Standardized effect sizes were small for most markers, adherence to recommendations was not measured objectively, and the follow-up was short.